Simmunome Inc.
Machine Learning · LLM & Generative AI
Overview
Simmunome offers a genAI platform that utilizes mechanistic modeling combined with machine learning to simulate the efficacy and safety of drug targets, enhancing transnational R&D.
Funding and backers
Total raised
$2M
1 round on record
Latest round
$2M
Venture round · Sep 2023 · 3 yr ago
Team
51-200
employees, estimated range
Backers
3
Plug and Play, Bkrcapital
The money's age
Long since its last round
37 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 18, 2023
Raised a round Venture round $2M · BetaKit
Aug 1, 2023
Partnership ILIKOS Consulting Group and Simmunome Announce Strategic Partnership · PRNewswire
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2023 | $2M | — | BetaKit |
Backed byfrom the funds' portfolios and accelerator catalogs
Plug and Play 
Bkrcapital 
Frontrow Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Research in agent interaction, machine learning, and systems infrastructure for robotics control.
Solving the last frontier in machine intelligence with the bitter lesson. Research in agent interaction, machine learning, and systems…
Democratizing access to AI. Machine Learning and Deep Learning algorithms require large amounts of data to be trained.
Customer AI from OCX Cognition represents a new category of enterprise customer analytics software comprised of configurable…
Lantern uses cutting-edge machine learning to guide what, when, and how distributors buy.
Generating a chemical atlas for treating human disease. Our ATLAS technology merges AcTive® Learning with Automated Synthesis and…
Financials
Total raised
$2M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2023 | $2M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation
Merck Digital Sciences Studio Opens in Canada to Accelerate Biopharmaceutical Innovation New accelerator program to support startups with funding, mentorship and technology resources Download KIRKLAND, QC., June 20, 2025 - Merck, known as MSD outside of t
Read more
Report
Simmunome: Revolutionizing drug development with tech bio innovation
Founded in 2019 by Armstrong Murira and Nardin Nakhla, Simmunome stands out as a pioneering Canadian techbio startup. While traditional biotech companies focus on developing therapeutics, Simmunome takes a different approach: applying advanced technology
Read more
Report
Simmunome：以技術生物創新顛覆藥物開發
Simmunome是一家由Armstrong Murira和 Nardin Nakhla於 2019 年創立的加拿大創新技術生物techbio公司與專注於研發治療產品的傳統生物科技biotech公司不...
Read more
Report
Simmunome secures $2 million to make clinical trials more efficient with AI
Using artificial intelligence, Montréal-based Simmunome aims to help predict whether drug candidates will succeed or fail in clinical trials.
Read more
Report
ILIKOS Consulting Group and Simmunome Announce Strategic Partnership aimed at:
/PRNewswire/ -- With the average new drug taking 10 years in clinical development, combined with a $2B+ price tag and 90% failure rate, the clinical research...
Read more
Report
ILIKOS Consulting Group and Simmunome Announce Strategic Partnership
/PRNewswire/ -- With the average new drug taking 10 years in clinical development, combined with a $2B+ price tag and 90% failure rate, the clinical research...
Read more
Report